106 related articles for article (PubMed ID: 25638543)
1. Looking for predictive markers in breast cancer--authors' reply.
Gligorov J
Lancet Oncol; 2015 Jan; 16(1):e1-2. PubMed ID: 25638543
[No Abstract] [Full Text] [Related]
2. Looking for predictive markers in breast cancer.
Bonotto M; Fontanella C; Puglisi F
Lancet Oncol; 2015 Jan; 16(1):e1. PubMed ID: 25638542
[No Abstract] [Full Text] [Related]
3. Length of chemotherapy and use of bevacizumab for breast cancer.
Brufsky A
Lancet Oncol; 2014 Nov; 15(12):1285-7. PubMed ID: 25439683
[No Abstract] [Full Text] [Related]
4. Breast cancer: combining bevacizumab with chemotherapy--from maintenance to second-line treatment.
Errico A
Nat Rev Clin Oncol; 2014 Nov; 11(11):621. PubMed ID: 25311354
[No Abstract] [Full Text] [Related]
5. [Optimal chemotherapy for advanced and recurrent breast cancer patients].
Masuda N
Nihon Rinsho; 2007 Jun; 65 Suppl 6():523-9. PubMed ID: 17682205
[No Abstract] [Full Text] [Related]
6. Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial.
Gligorov J; Doval D; Bines J; Alba E; Cortes P; Pierga JY; Gupta V; Costa R; Srock S; de Ducla S; Freudensprung U; Mustacchi G
Lancet Oncol; 2014 Nov; 15(12):1351-60. PubMed ID: 25273343
[TBL] [Abstract][Full Text] [Related]
7. Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer.
Lück HJ; Lübbe K; Reinisch M; Maass N; Feisel-Schwickardi G; Tomé O; Janni W; Aydogdu M; Neunhöffer T; Ober A; Aktas B; Park-Simon TW; Schumacher C; Höffkes HG; Illmer T; Wagner H; Mehta K; von Minckwitz G; Nekljudova V; Loibl S
Breast Cancer Res Treat; 2015 Jan; 149(1):141-9. PubMed ID: 25519041
[TBL] [Abstract][Full Text] [Related]
8. In reply.
Xu B; Seidman A; Chan S
Oncologist; 2015 Jan; 20(1):88. PubMed ID: 25589501
[TBL] [Abstract][Full Text] [Related]
9. [Combination therapy herceptin+xeloda].
Schaller G
Onkologie; 2002 Dec; 25 Suppl 5():17-8; discussion 19. PubMed ID: 23573615
[No Abstract] [Full Text] [Related]
10. State-of-the-art chemotherapy for advanced breast cancer.
Piccart MJ; Awada A
Semin Oncol; 2000 Oct; 27(5 Suppl 9):3-12. PubMed ID: 11049051
[TBL] [Abstract][Full Text] [Related]
11. Brain metastases from HER2-positive breast cancer - authors' reply.
Bachelot T; Cropet C; Diéras V; Jimenez M; Campone M
Lancet Oncol; 2013 Jan; 14(1):e3-4. PubMed ID: 23276371
[No Abstract] [Full Text] [Related]
12. Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
Miles D; Zielinski C; Martin M; Vrdoljak E; Robert N
Eur J Cancer; 2012 Mar; 48(4):482-91. PubMed ID: 22257791
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in breast cancer: fundamental questions remain.
Miles DW
Lancet Oncol; 2013 Feb; 14(2):99-101. PubMed ID: 23369679
[No Abstract] [Full Text] [Related]
14. Capecitabine and docetaxel combination for the treatment of breast cancer.
Morishita M; Leonard RC
Womens Health (Lond); 2008 Jan; 4():11-22. PubMed ID: 19072447
[TBL] [Abstract][Full Text] [Related]
15. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.
Glück S; Ross JS; Royce M; McKenna EF; Perou CM; Avisar E; Wu L
Breast Cancer Res Treat; 2012 Apr; 132(3):781-91. PubMed ID: 21373875
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab and capecitabine for metastatic breast cancer.
Med Lett Drugs Ther; 1998 Nov; 40(1039):106-8. PubMed ID: 9814369
[No Abstract] [Full Text] [Related]
18. Bevacizumab: the phoenix of breast oncology?
Andre F; Deluche E; Bonnefoi H
Lancet Oncol; 2015 Jun; 16(6):600-1. PubMed ID: 25975636
[No Abstract] [Full Text] [Related]
19. Treatment of HER2-positive metastatic breast cancer.
van Ramshorst MS; Sonke GS
N Engl J Med; 2015 May; 372(20):1964. PubMed ID: 25970057
[No Abstract] [Full Text] [Related]
20. Treatment of HER2-positive metastatic breast cancer.
Swain SM; Clark E; Baselga J
N Engl J Med; 2015 May; 372(20):1964-5. PubMed ID: 25970056
[No Abstract] [Full Text] [Related]
[Next] [New Search]
